NCT06818305View on ClinicalTrials.gov

Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: a Multicenter RCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

December 31, 2027

Conditions
Renal Cell Carcinoma (Kidney Cancer)Renal Cell Carcinoma (RCC)NephrectomyChronic Kidney Disease(CKD)
Interventions
DRUG

Finerenone (BAY 94-8862)

"Adjusting lifestyle and managing underlying conditions according to the Chronic Kidney Disease Early Screening, Diagnosis, and Prevention Guidelines (2022 Edition) + Finerenone (10mg/d or 20mg/d)."

DRUG

Empagliflozin 10 mg

"Adjusting lifestyle and managing underlying conditions according to the Chronic Kidney Disease Early Screening, Diagnosis, and Prevention Guidelines (2022 Edition) + Empagliflozin (10mg/d)."

Trial Locations (1)

210000

RECRUITING

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Nanjing

All Listed Sponsors
collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

collaborator

Qilu Hospital of Shandong University

OTHER

collaborator

Yantai Yuhuangding Hospital

OTHER

collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

lead

Jinling Hospital, China

OTHER